Ocular Hypertension Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's 'Ocular Hypertension Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology, as well as the Ocular Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Ocular Hypertension Treatment Market Report @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Ocular Hypertension Market Report
• In May 2026, OcuVex Therapeutics, received a Complete Response Letter (CRL) from the US FDA. The CRL pertains to the New Drug Application (NDA) for PDP-716, a novel once-daily ophthalmic suspension intended for the treatment of glaucoma.
• In February 2026, Nicox highlighted positive NCX 470 phase III data confirming therapeutic profile at the 2026 American Glaucoma Society Annual Meeting. The data demonstrated best-inclass IOP lowering efficacy of up to 10mmHg from baseline which has met the efficacy requirements for a New Drug Application (NDA) in the US. and China.
• In February 2026, Nicox announced that it has received positive written feedback from its NCX 470 pre-NDA (New Drug Application) meeting with the US FDA.
• Among EU4 and the UK, Germany accounted for the highest number of cases whereas Spain accounted for the least number of cases in 2025.
• Females are more affected than males with ocular hypertension.
• Japan accounted for approximately 20% of prevalent cases of ocular hypertension among the 7MM.
• The leading Ocular Hypertension Companies include Glaukos, Santen, UBE Corporation, Allergan, Nicox Ophthalmics, Sun Pharma Advanced Research Company, Visiox Pharma, Santen, Ono Pharmaceutical, and others.
• Promising Ocular Hypertension Therapies include Travoprost intracameral implant (iDose TR), Omidenepag Isopropyl Ophthalmic Solution (OMLONTI), Bimatoprost implant (DURYSTA), NCX 470, PDP-716, Sepetaprost (DE-126/ONO-9054/STN1012600), and others.

Get a Free sample for the Ocular Hypertension Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ocular Hypertension Overview
Ocular hypertension is a condition characterized by elevated IOP without detectable optic nerve damage or visual field loss associated with glaucoma. It occurs when the aqueous humor inside the eye does not drain properly, leading to increased pressure within the eye. Although ocular hypertension itself may not initially cause symptoms, it is considered a significant risk factor for the development of open-angle glaucoma if left untreated.

Ocular Hypertension Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Ocular Hypertension
• Gender-specific Cases of Ocular Hypertension
• Age-specific Cases of Ocular Hypertension
• Treated Cases of Ocular Hypertension

Download the report to understand which factors are driving Ocular Hypertension Epidemiology trends @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Approved Therapies for Ocular Hypertension
• Travoprost Intracameral Implant (iDose TR): Glaukos
iDose TR is a first-of-its-kind, long-duration, anchored intracameral procedural pharmaceutical therapy designed to continuously (24/7) deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose TR is indicated for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension. iDose TR is composed of a biocompatible intracameral implant preloaded in a sterile, single-dose inserter.

• Omidenepag Isopropyl Ophthalmic Solution (OMLONTI): Santen and UBE Corporation
OMLONTI is a novel ophthalmic therapy approved for the reduction of elevated IOP in patients with OAG and ocular hypertension. It contains omidenepag isopropyl, a selective prostaglandin E2 (EP2) receptor agonist that lowers IOP by enhancing both trabecular and uveoscleral aqueous humor outflow pathways. The FDA approval for OMLONTI was based on data from 12 clinical studies conducted in multiple global locations. Notably, a US Phase III study confirmed OMLONTI to be non-inferior to timolol, the standard of care. Two different Phase III studies conducted in Japan and Asia showed OMLONTI to be non-inferior to latanoprost, another standard of care. It is the first approved therapy with this unique EP2 receptor mechanism of action. OMLONTI is administered as a once-daily ophthalmic solution (0.002%), typically dosed in the evening.

Discover more about therapies set to grab Major Ocular Hypertension Market Share @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ocular Hypertension Pipeline Analysis
• NCX 470: Nicox Ophthalmics
NCX 470 is considered a next-generation prostaglandin analog and represents Nicox's lead clinical asset. It is an investigational nitric oxide donating bimatoprost ophthalmic solution being developed for the treatment of OAG and ocular hypertension. The therapy combines bimatoprost with nitric oxide-mediated trabecular meshwork relaxation to enhance aqueous humor outflow and improve IOP reduction versus conventional prostaglandin analogs like latanoprost. In Phase III trials, including Mont Blanc and Denali, NCX 470 demonstrated non-inferior and numerically superior IOP lowering versus latanoprost at multiple timepoints while maintaining a favorable tolerability profile. The drug successfully completed Phase III clinical trials, with topline results reported in August 2025. The company further anticipates submitting the NDA for NCX 470 in 2026.

• PDP-716: Sun Pharma Advanced Research Company (SPARC)/Ocuvex Therapeutics
PDP-716 by Sun Pharma Advanced Research Company is an investigational once-daily ophthalmic suspension of brimonidine tartrate 0.35% being developed for the treatment OAG and ocular hypertension. Developed using SPARC's proprietary TearAct technology, PDP-716 is designed to provide sustained drug delivery and improved bioavailability, enabling once-daily dosing compared with currently marketed brimonidine formulations that require three-times-daily administration. In a pivotal Phase III trial, PDP-716 met its primary endpoint by demonstrating intraocular pressure (IOP) reduction comparable to Alphagan P 0.1% dosed three times daily, with a similar safety profile. PDP-716 was licensed by SPARC to Visiox Pharmaceuticals in 2021 for global development and commercialization rights outside India and Greater China; in 2024, Visiox Pharmaceuticals merged with Ocuvex Therapeutics.

Ocular Hypertension Companies
Glaukos, Santen, UBE Corporation, Allergan, Nicox Ophthalmics, Sun Pharma Advanced Research Company, Visiox Pharma, Santen, Ono Pharmaceutical, and others.

Ocular Hypertension Market Outlook
Overall, the ocular hypertension market across the 7MM is expected to witness steady growth from 2026 to 2036, driven by increasing disease prevalence, aging populations, improved screening rates, and continued innovation in ophthalmic therapeutics. The growing adoption of sustained-release implants, minimally invasive treatment approaches, and differentiated topical therapies is anticipated to reshape the competitive landscape.

Ocular Hypertension Treatment Landscape
The treatment landscape for ocular hypertension has evolved significantly from conventional topical IOP-lowering therapies toward long-acting implants and novel mechanism-based agents aimed at improving efficacy, durability, and patient adherence. Approved therapies such as travoprost intracameral implant (iDose TR), omidenepag isopropyl ophthalmic solution (OMLONTI), and bimatoprost implant represent important advancements in sustained drug delivery and alternative prostaglandin receptor targeting. These therapies are addressing major unmet needs associated with poor adherence to daily eye drops and fluctuations in IOP control, while also improving long-term disease management in patients at risk of glaucoma progression. Investigational candidates such as NCX 470, PDP-716, and Sepetaprost (DE-126/ONO-9054/STN1012600) are being developed to provide superior IOP reduction, improved tolerability, and longer duration of action compared with currently available therapies. NCX 470 combines nitric oxide donation with prostaglandin activity to enhance aqueous humor outflow, while PDP-716 utilizes sustained-release brimonidine technology to enable once-daily dosing. However, the regulatory pathway for PDP-716 has encountered setbacks. The US FDA issued a Complete Response Letter (CRL) for the PDP-716 New Drug Application (NDA) in July 2023 due to unresolved facility inspection-related observations at a third-party Active Pharmaceutical Ingredient (API) manufacturing site, rather than concerns regarding the drug's safety or efficacy. SPARC and Ocuvex Therapeutics subsequently addressed the observations and resubmitted the NDA in late 2025. However, the FDA issued another CRL in May 2026, potentially extending timelines for approval and commercial launch.

To know more about Ocular Hypertension Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ocular Hypertension Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Ocular Hypertension Companies- Glaukos, Santen, UBE Corporation, Allergan, Nicox Ophthalmics, Sun Pharma Advanced Research Company, Visiox Pharma, Santen, Ono Pharmaceutical, and others.
• Ocular Hypertension Therapies- Travoprost intracameral implant (iDose TR), Omidenepag Isopropyl Ophthalmic Solution (OMLONTI), Bimatoprost implant (DURYSTA), NCX 470, PDP-716, Sepetaprost (DE-126/ONO-9054/STN1012600), and others.
• Ocular Hypertension Therapeutic Assessment- Ocular Hypertension current marketed and emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and market barriers
• Ocular Hypertension Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ocular Hypertension Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Explore more information about the Ocular Hypertension Therapeutics Market Report @ https://www.delveinsight.com/sample-request/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Ocular Hypertension
4. Key Events of Ocular Hypertension
5. Epidemiology and Market Methodology of Ocular Hypertension
6. Ocular Hypertension Market Overview at a Glance
7. Disease Background And Overview of Ocular Hypertension
8. Epidemiology and Patient Population of Ocular Hypertension
9. Patient Journey of Ocular Hypertension
10. Marketed Therapies of Ocular Hypertension
11. Emerging Therapies of Ocular Hypertension
12. Ocular Hypertension: 7MM Analysis
13. Unmet Needs of Ocular Hypertension
14. SWOT Analysis of Ocular Hypertension
15. KOL Views of Ocular Hypertension
16. Market Access and Reimbursement of Ocular Hypertension
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.